價(jià)格 | 詢價(jià) |
包裝 | 5mg |
最小起訂量 | 5mg |
發(fā)貨地 | 上海 |
更新日期 | 2025-04-10 |
中文名稱:Icotinib HCl (EGFR抑制劑) | 英文名稱:Icotinib HCl (EGFR抑制劑) |
有效期: 一年 | 產(chǎn)品類別: 免疫與炎癥 Jak/Stat:IL-6 Signaling |
產(chǎn)品編號(hào) | 產(chǎn)品名稱 | 產(chǎn)品包裝 | 產(chǎn)品價(jià)格 |
SD4767-5mg | Icotinib HCl (EGFR抑制劑) | 5mg | 詢價(jià) |
化學(xué)信息:
化學(xué)名 | N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine hydrochloride |
![]() |
簡(jiǎn)稱 | Icotinib HCl | |
別名 |
Icotinib Hydrochloride, BPI-2009H |
|
中文名 | 凱美納 | |
化學(xué)式 | C22H22ClN3O4 | |
分子量 | 427.88 | |
CAS號(hào) | 1204313-51-8 | |
純度 | 98% | |
溶劑/溶解度 |
Water<1mg/ml; DMSO5mg/ml; Ethanol<1mg/ml |
|
溶液配制 | 5mg加入1.17ml DMSO,或者每4.28mg加入1ml DMSO,配制成10mM溶液。SD4767-10mM用DMSO配制。 |
生物信息:
產(chǎn)品描述 | Icotinib hydrochloride is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). | ||||
信號(hào)通路 | JAK/STAT; Protein Tyrosine Kinase | ||||
靶點(diǎn) | EGFR and EGFR mutants | - | - | - | - |
IC50 | 5nM | - | - | - | - |
體外研究 | Icotinib inhibits EGFR activity in a dose-dependent manner, with an IC50value of 5nM and complete inhibition at 62.5nM. Icotinib selectively solely inhibits the EGFR members including the wild type and mutants with inhibition efficacies of 61-99%. Icotinib blocks EGFR-mediated intracellular tyrosine phosphorylation in human epidermoid carcinoma A431 cells in a dose-dependent manner. Meanwhile, in our proliferation assay performed on A431, BGC-823, A549, H460, HCT8, KB and Bel-7402 cell lines, we found that the relative sensitivity of cell lines to Icotinib is A431 > BGC-823 > A549 > H460 > KB > HCT8 and Bel-7402. Icotinib exhibits a broad spectrum of antitumor activity and it is especially effective against tumors expressing higher levels of EGFR. | ||||
體內(nèi)研究 | In vivo studies demonstrated that Icotinib exhibited potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug was well tolerated at doses up to 120mg/kg/day in mice without mortality or significant body weight loss during the treatment. A head to head randomized, double blind phase III trial using Gefitinib as an active control for patients with advanced non-small cell lung cancer (NSCLC) was finished recently (Trial registration ID: NCT01040780). | ||||
臨床實(shí)驗(yàn) | N/A | ||||
特征 | N/A |
相關(guān)實(shí)驗(yàn)數(shù)據(jù)(此數(shù)據(jù)來自于公開文獻(xiàn),碧云天并不保證其有效性):
酶活性檢測(cè)實(shí)驗(yàn) | |
方法 | N/A |
細(xì)胞實(shí)驗(yàn) | |
細(xì)胞系 | N/A |
濃度 | N/A |
處理時(shí)間 | N/A |
方法 | N/A |
動(dòng)物實(shí)驗(yàn) | |
動(dòng)物模型 | N/A |
配制 | N/A |
劑量 | N/A |
給藥方式 | N/A |
產(chǎn)品編號(hào) | 產(chǎn)品名稱 | 包裝 |
SD4767-10mM | Icotinib HCl (EGFR抑制劑) | 10mM×0.2ml |
SD4767-5mg | Icotinib HCl (EGFR抑制劑) | 5mg |
SD4767-25mg | Icotinib HCl (EGFR抑制劑) | 25mg |
— | 說明書 | 1份 |
保存條件:
????????-20℃保存,至少一年有效。5mg和25mg包裝也可室溫保存,至少6個(gè)月有效。如果溶于非DMSO溶劑,建議分裝后-80℃保存,預(yù)計(jì)6個(gè)月內(nèi)有效。
成立日期 | 2007-07-19 (18年) | 注冊(cè)資本 | 1000.000000萬人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 500萬-1000萬 |
主營(yíng)行業(yè) | 生化試劑,核苷,核苷酸,寡核苷酸,抗體,蛋白組學(xué),生物活性小分子 | 經(jīng)營(yíng)模式 | 試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-04-23 | |
詢價(jià) |
VIP6年
|
廣州優(yōu)南科技有限公司
|
2025-04-08 | |
¥1969.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-03-24 |